The imaging technique at the heart of the study, positron emission tomography combined with computed tomography, has become a cornerstone of modern cancer care. Patients receive an injection of [18F]-fluorodeoxyglucose, a radioactive glucose analog that is avidly taken up by metabolically active cells. Because cancer cells typically consume glucose at a far higher rate than healthy tissue, they light up on the resulting images, allowing physicians to visualize both the primary tumor and any spread to lymph nodes or distant organs. The PET component reveals metabolic activity, while the CT component provides detailed anatomical context, and the fusion of the two gives clinicians a map of where active disease resides in the body.

In the standard workflow for locally advanced cervical cancer, PET-CT is used twice: once before treatment begins, to establish the stage of the disease, and again several weeks after chemoradiotherapy has concluded, to assess how well the cancer responded. The Swedish team set out to determine whether the information gathered at that second time point could do more than simply confirm whether the tumor had shrunk. They wanted to know whether the pattern of metabolic response could serve as a genuine prognostic instrument, capable of stratifying patients into distinct risk categories that would justify different follow-up strategies or, potentially, additional interventions.

To quantify treatment response, the researchers extracted three complementary parameters from every scan. The first and most widely used is SUVmax, the maximum standardized uptake value, which reflects the peak glucose metabolism within the most active region of a lesion. The second is metabolic tumour volume, or MTV, which measures the total physical volume of tissue exhibiting abnormally high FDG uptake. The third is total lesion glycolysis, or TLG, which combines volume and intensity into a single figure representing the overall metabolic burden carried by the disease. Each parameter captures a different dimension of tumor biology, and the team analyzed all three separately to see whether the more computationally demanding volume-based measures offered any advantage over the simple maximum uptake value.

Using these parameters, the investigators classified each patient’s post-treatment response into one of four categories adapted from established response criteria. A complete metabolic response, or CMR, meant the total resolution of abnormal FDG uptake in all lesions, essentially signaling that no metabolically active cancer could be detected anywhere in the scanned field. A partial metabolic response, or PMR, was defined as a reduction of more than 25 percent in SUVmax, MTV or TLG, indicating that disease remained but had been substantially weakened. Progressive metabolic disease, or PMD, was declared when uptake increased by more than 25 percent or when new FDG-avid lesions appeared, a clear sign that the treatment had failed to contain the cancer. Patients who fit none of these categories were classified as having stable disease. Because the number of events in the PMR and stable disease groups was limited, the researchers combined them into a single intermediate group for statistical analysis.

The results were striking. Taking patients with complete metabolic response as the reference group, those with partial response or stable disease faced roughly 1.2 times the odds of experiencing a recurrence, a modest but measurable elevation in risk. Far more dramatic was the picture for patients whose disease progressed: their odds of recurrence were 1.7 times higher when response was assessed by SUVmax, and 1.8 times higher when assessed by MTV or TLG. In other words, a scan showing growing or newly emerged metabolically active disease after treatment was a red flag that recurrence was substantially more likely, regardless of which of the three parameters was used to make the call.

The survival analysis carried an even starker message. Patients in the intermediate response group had a hazard ratio for death of 4.0 when response was measured by SUVmax, meaning their risk of dying during the follow-up period was four times that of patients who achieved a complete metabolic response. When MTV or TLG served as the response metric, the hazard ratio for this intermediate group was 2.9. For patients with progressive metabolic disease, the hazard ratio soared to 16.0 across all three parameters, a sixteen-fold increase in mortality risk compared with complete responders. The concordance index, a statistical measure of how well a model discriminates between patients with different outcomes, reached 0.84 for SUVmax-based models and 0.86 for models built on MTV or TLG, values that indicate strong predictive performance for any prognostic tool in oncology.

Perhaps the most consequential finding of the study is what it did not find: no meaningful superiority of the sophisticated volume-based parameters over the simple maximum uptake value. MTV and TLG require semi-automated segmentation of tumor volumes and considerably more computational processing, and some researchers have argued that their added information content should translate into better prognostic power. In this cohort, however, the three parameters performed in a nearly identical fashion, with concordance indices differing by only two hundredths. For clinical practice, this is genuinely good news, because it suggests that the prognostic value of post-treatment PET-CT can be unlocked using a parameter that is already routinely reported by nuclear medicine departments worldwide, without the need for new software, additional training or workflow changes.

The implications for patient management are considerable. Patients who achieve a complete metabolic response could potentially be spared intensive surveillance, receiving standard follow-up with the reassurance that their statistical outlook is excellent. Those with partial or stable metabolic response, whose risk is elevated but not extreme, might benefit from closer imaging intervals and a lower threshold for biopsy or salvage interventions. Patients showing progression on the post-treatment scan represent the group with the most urgent need for attention, and the sixteen-fold hazard ratio suggests that early escalation of care, whether through additional systemic therapy or enrollment in clinical trials of novel agents, could be life-extending for this small but high-risk population. The study also reinforces the value of performing a post-treatment PET-CT at all, since the metabolic information it provides clearly carries prognostic weight beyond anatomical assessment alone.

As with all retrospective single-center analyses, the findings come with caveats. The 133 patients were treated at a single Swedish institution, and the classification thresholds, including the 25 percent change criteria, were drawn from established response frameworks rather than derived de novo. Prospective validation in larger and more diverse cohorts will be needed before response category can be formally incorporated into treatment guidelines. Nevertheless, the strength and consistency of the associations, spanning recurrence risk, overall survival and three independent metabolic parameters, make a compelling case that the post-treatment FDG-PET/CT scan is far more than a formality. It is, in effect, a crystal ball of glucose metabolism, offering each patient and her medical team an early, individualized forecast of the road ahead, and pointing the way toward a future in which follow-up care for cervical cancer is tailored not to the average patient but to the biology revealed on a single scan.

Subject of Research: FDG-PET/CT-based treatment response assessment as a predictor of recurrence and survival in locally advanced cervical cancer

Article Title: FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer

Article References: Markus, M., Sartor, H., Bjurberg, M., Minarik, D., & Trägårdh, E. (2026). FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer. BMC Medical Imaging, 26(1), Article 458. https://doi.org/10.1186/s12880-026-02772-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02772-8

Keywords: FDG-PET/CT, cervical cancer, treatment response, SUVmax, metabolic tumour volume, total lesion glycolysis, recurrence, overall survival, radiotherapy, nuclear medicine, predictive medicine, oncology

The imaging technique at the heart of the study is ¹⁸F-fluorodeoxyglucose PET/CT, a hybrid technology that pairs the functional sensitivity of positron emission tomography with the anatomical detail of computed tomography. Fluorine-18 labelled fluorodeoxyglucose is a radioactive glucose analogue that cells import through the same transporters they use for ordinary sugar. Because most cancer cells run their metabolism on glycolysis even when oxygen is plentiful, the Warburg effect, malignant tissue accumulates the tracer far more avidly than surrounding healthy structures. A detector ring records the decay of the fluorine-18 isotope, and the resulting signal is converted into standardised uptake values, or SUVs, which quantify how intensely a given lesion traps glucose relative to the injected dose and body mass. The maximum standardised uptake value, SUVmax, captures the single hottest pixel within a lesion and has long served as a convenient, if imperfect, proxy for metabolic aggressiveness.

The Zhejiang team, led by Yunqi Zhu and corresponding author Xinhui Su, assembled thirty treatment-naïve patients with histologically confirmed testicular germ cell tumours who had undergone ¹⁸F-FDG PET/CT before any antitumour therapy. Twelve carried a diagnosis of seminoma and eighteen had non-seminomatous germ cell tumours, a group that encompasses embryonal carcinoma, yolk sac tumour, choriocarcinoma and other histologies, often in mixtures. Because the patients had not yet received chemotherapy, surgery or radiotherapy, the scans offered an unfiltered view of each tumour’s native metabolism, free from the confounding effects of treatment-induced inflammation or necrosis that plague post-therapy imaging.

The headline result is hard to overstate. Non-seminomatous tumours showed a median primary-tumour SUVmax of 16.66, compared with just 8.41 for seminomas, a difference that reached statistical significance at P equals 0.007. When the researchers looked instead at the hottest lesion anywhere in each patient, the gap widened further: 21.91 versus 8.41, with P below 0.001. In other words, the non-seminomatous tumours were burning through glucose at roughly twice the rate of their seminoma counterparts, a metabolic distinction that mirrors the known biological gulf between these entities. Non-seminomatous germ cell tumours tend to be more proliferative, more genetically chaotic and more prone to early haematogenous spread, and the PET data appear to capture that ferocity in a single number.

Disease extent itself was also strikingly different between the groups. Distant metastatic disease, classified as M1 under the American Joint Committee on Cancer staging system, was present in 55.6 percent of the non-seminomatous patients but only 8.3 percent of those with seminoma. This imbalance matters for interpretation, because a patient-level measurement such as the highest-lesion SUVmax can be inflated simply by the presence of a metabolically hot metastasis rather than by any intrinsic property of the primary tumour. The investigators were alert to this pitfall and designed their analyses accordingly, performing receiver operating characteristic analysis to compare diagnostic performance, restricting analyses to patients without distant metastases, and building exploratory multivariable models to adjust for tumour size and metastatic status.

Those sensitivity analyses proved revealing. When the analysis was confined to patients with M0 disease, meaning no distant metastases, the primary-tumour SUVmax remained significantly higher in non-seminomatous tumours, at 16.96 versus 8.00 with P equal to 0.001. However, the apparent advantage of the patient-level highest-lesion SUVmax over the primary-tumour measurement shrank dramatically: the difference in area under the receiver operating characteristic curve fell from 0.148 in the full cohort to just 0.023 in the metastasis-free subgroup. This tells an important story about what each metric actually measures. The highest-lesion SUVmax looked like a superb discriminator across all comers, achieving an apparent area under the curve of 0.944, but part of that performance was borrowed from the fact that metastatic spread is itself more common in non-seminomatous disease. The primary-tumour measurement, by contrast, appears to reflect genuine histology-linked biology.

The exploratory log-linear model drove the point home. After adjusting for primary-tumour size and M status, non-seminomatous tumours retained a higher primary-tumour SUVmax, with an adjusted geometric mean ratio of 1.67 relative to seminoma and a 95 percent confidence interval of 1.07 to 2.60, yielding P equal to 0.024. A geometric mean ratio of 1.67 implies that, on average, the non-seminomatous primary tumours took up roughly two-thirds more glucose than seminomas of comparable size and stage. For a single-centre study of thirty patients, this is an encouraging signal, though the authors are careful to label the modelling as exploratory and to emphasise that validation in larger independent cohorts is essential before any clinical application.

The study also placed PET-derived parameters alongside the traditional serum tumour markers that clinicians already use. Among individual biomarkers, the patient-level highest-lesion SUVmax showed the highest apparent discrimination with an area under the curve of 0.944, followed by alpha-fetoprotein at 0.910 and primary-tumour SUVmax at 0.796. Alpha-fetoprotein is a well-established hallmark of non-seminomatous histology, since seminomas do not produce it, so its strong showing is unsurprising. What is intriguing is that a purely metabolic imaging metric could rival a specific biochemical marker, suggesting that glucose avidity and embryonal differentiation are intertwined at a fundamental level. The researchers also computed a panel of volumetric parameters, including metabolic tumour volume, total lesion glycolysis and total metabolic tumour volume, which quantify not just how bright a lesion is but how much metabolically active tissue it contains, though the SUVmax comparisons dominated the significant findings.

Why should two tumours arising from the same primordial germ cell lineage differ so markedly in their sugar consumption? Seminomas are histologically homogeneous, composed of sheets of uniform cells resembling primitive spermatogonia, whereas non-seminomatous tumours can contain wildly divergent components, from gland-like yolk sac structures to syncytiotrophoblasts that secrete human chorionic gonadotropin. Embryonal carcinoma elements, in particular, are highly proliferative and express patterns of gene activity reminiscent of pluripotent stem cells, states that are metabolically expensive. Rapid proliferation demands nucleotide synthesis, lipid production and continuous ATP generation, all of which push cells toward intensified glycolysis and upregulated glucose transporters. The doubled SUVmax observed in non-seminomatous tumours is thus plausibly a readout of this underlying developmental chaos, though the study was not designed to identify the molecular mechanisms responsible.

The practical implications, if confirmed, could be meaningful. A pretreatment PET/CT that hints at histology could help clinicians anticipate the tumour type in settings where biopsy material is limited or ambiguous, flag patients at higher risk of harboring metastatic disease, and potentially refine surveillance strategies after orchiectomy. The authors themselves are appropriately measured, describing their work as a retrospective exploratory study of thirty patients from a single centre and calling for validation in larger, independent and ideally prospective cohorts. Such studies would need to address selection bias, scanner variability across institutions and the heterogeneity of non-seminomatous histologies. Still, the core observation stands out for its simplicity: before a single drop of chemotherapy, the two great families of testicular germ cell tumour already glow differently on a glucose scan, and that difference survives statistical scrutiny even when tumour size and spread are taken into account. It is a vivid reminder that cancer metabolism is not merely a byproduct of malignancy but a window into what a tumour truly is.

Subject of Research: Metabolic characteristics of testicular germ cell tumours on pretreatment ¹⁸F-FDG PET/CT imaging

Article Title: Pretreatment ¹⁸F-FDG PET/CT metabolic characteristics of seminoma and non-seminomatous testicular germ cell tumours: a retrospective exploratory study

Article References: Zhu, Y., Lu, X., Lin, L., Wang, H., Yu, Q., & Su, X. (2026). Pretreatment ¹⁸F-FDG PET/CT metabolic characteristics of seminoma and non-seminomatous testicular germ cell tumours: a retrospective exploratory study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02855-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02855-6

Keywords: testicular cancer, testicular germ cell tumour, seminoma, non-seminomatous germ cell tumour, ¹⁸F-FDG PET/CT, SUVmax, tumour metabolism, metabolic tumour volume, alpha-fetoprotein, cancer imaging, BMC Medical Imaging, diagnostic imaging